What happens when you stop taking semaglutide
The clearest evidence we have says weight regain is common after semaglutide is stopped.
In the STEP 1 trial extension, researchers followed 327 participants for one year after semaglutide 2.4 mg once weekly and the associated lifestyle intervention were withdrawn. During that year, participants regained much of the weight they had previously lost.
Put another way, participants regained about two-thirds of the weight they had lost within one year of stopping treatment. They were still, on average, 5.6% below their original body weight at the end of that year.
That is the best-known semaglutide withdrawal result. But it is a group average from an exploratory extension, not a prediction about any individual person.
What did the STEP 1 extension actually study?
STEP 1 originally enrolled 1,961 adults with overweight or obesity who did not have diabetes.
Participants were randomized to semaglutide 2.4 mg once weekly or placebo for 68 weeks, alongside a lifestyle intervention that included reduced-calorie diet and increased physical activity.
The extension followed 327 participants who completed the original 68-week trial. They came from a pre-selected subset of trial sites in Canada, Germany, the UK, the US, and Japan rather than the full trial population.
Among those who had received semaglutide, average weight loss from the beginning of the study through week 68 was substantial. After treatment was stopped, regain began.
By week 120, their average weight remained 5.6% below where they had started.
The researchers also tracked cardiometabolic measures. Many of the improvements observed during treatment, including changes in blood pressure and metabolic markers, moved back toward baseline after treatment ended.
The authors described the extension analyses as exploratory. That matters. The extension provides useful evidence about what happened after withdrawal in this group, but it was not designed with the same statistical rigor as the primary randomized trial.
Why can weight return after semaglutide is stopped?
The simplest explanation is that semaglutide changes appetite and food intake while the drug is active in the body. When treatment stops and the drug clears, those effects can fade.
Controlled human studies support the first part of that explanation.
In a randomized study of 72 adults with obesity, semaglutide 2.4 mg was associated with lower hunger, reduced prospective food consumption, and improved control of eating compared with placebo. Participants also consumed less energy at an ad libitum lunch (a meal where they could eat as much or as little as they wanted).
An earlier randomized crossover study in 30 adults with obesity, using doses up to 1.0 mg rather than the 2.4 mg weekly dose in the STEP trials, also found that semaglutide reduced appetite and energy intake and improved eating control.
These studies help explain why stopping treatment can matter.
Semaglutide is not simply associated with weight loss while leaving appetite regulation untouched. During treatment, appetite-related measures moved in the direction of lower intake.
When treatment ends, there is no reason to assume those drug-related effects will remain unchanged indefinitely.
What the studies do not establish is a precise sequence such as "appetite returns by day X" or that every person experiences the same pattern. Human appetite regulation is complex, and the reviewed trials did not map individual timelines after withdrawal in detail.
Does everyone regain all the weight?
No. The STEP 1 extension does not support that claim.
Participants regained about two-thirds of their previous weight loss. At the end of the extension, the semaglutide group remained an average of 5.6% below baseline weight.
An average also hides substantial individual variation.
Some participants regained more. Others regained less. The study does not provide a rule that can predict an individual's outcome.
It is therefore more accurate to say that substantial regain was common in this study than to say that everyone returns to their starting weight.
What do maintenance studies show?
A separate randomized trial, STEP 4, tested the question from another direction.
All participants initially received semaglutide during a 20-week run-in. The 803 participants who reached the target dose and continued were then randomized to either continue semaglutide or switch to placebo for another 48 weeks.
Participants had already lost an average of 10.6% of their body weight during the initial semaglutide run-in.
From week 20 through week 68, those who continued semaglutide lost another 7.9% on average. Those switched to placebo regained 6.9% on average.
That randomized comparison strengthens the evidence that continued treatment and withdrawal produce different weight trajectories.
It does not answer every maintenance question.
STEP 4 compared continued semaglutide with withdrawal under specific trial conditions. It does not establish what happens under every possible maintenance strategy, including different lifestyle programs, different doses, or different durations of initial treatment.
The STEP 1 extension also stopped the structured lifestyle intervention at the same time as the study drug. That means the extension describes what happened after both supports ended together, not what would happen if lifestyle support continued while only the drug was withdrawn.
Can lifestyle changes prevent regain after stopping?
The studies reviewed here do not establish that a particular lifestyle strategy prevents post-semaglutide regain.
That is an important gap.
STEP 1 tells us what happened when both semaglutide and the trial lifestyle intervention ended. STEP 4 tells us that continued semaglutide outperformed placebo after a run-in period. Neither study establishes a proven formula for maintaining the full weight reduction after semaglutide is stopped.
That does not mean maintenance without semaglutide is impossible. It means these trials do not give us a tested protocol for doing so.
What the STEP 1 result cannot predict
The often-repeated "two-thirds regained" figure needs context.
It does not mean every person regains two-thirds of their lost weight.
It does not mean everyone returns to their original weight.
It does not tell us exactly how quickly an individual's appetite or weight will change.
And it does not establish what would happen under every possible maintenance strategy.
It describes the average outcome among participants in an exploratory extension of a specific clinical trial.
That is useful evidence. It is not an individual forecast.
Bottom line
Weight regain after stopping semaglutide is supported by human trial evidence, not just anecdote.
In the 327-person STEP 1 extension, participants who had received semaglutide regained about two-thirds of their previous weight loss within a year after treatment and the trial lifestyle program ended. They remained, on average, 5.6% below their starting weight.
STEP 4 points in the same direction. Participants randomized to continue semaglutide continued losing weight, while those switched to placebo regained weight.
The evidence therefore supports a straightforward conclusion: the weight effects observed during semaglutide treatment are not necessarily maintained after treatment stops.
What it cannot tell you is exactly what will happen to one person.
Stopping a prescribed medication is an individual treatment decision. Questions about whether to continue, taper, or stop semaglutide belong with the prescribing clinician, who can consider the full clinical picture.
Sources
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PMID: 35441470. DOI: 10.1111/dom.14725.
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728. DOI: 10.1001/jama.2021.3224.
Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754-762. PMID: 33269530. DOI: 10.1111/dom.14280.
Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251. PMID: 28266779. DOI: 10.1111/dom.12932.